New combo therapy aims to ease fibromyalgia pain

NCT ID NCT07208357

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares pregabalin alone versus pregabalin plus toludesvenlafaxine for fibromyalgia, a condition causing widespread pain and fatigue. Researchers will enroll 384 adults with moderate to severe pain that hasn't responded to non-drug treatments. The goal is to see if the combination provides better pain relief without more side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pregabalin and toludesvenlafaxine
What this could lead to
If successful, this combination could offer better pain relief for fibromyalgia patients than pregabalin alone, with manageable side effects.
What could go wrong
This is an early-phase study with no phase specified, so results may not confirm benefit. Side effects from the combination could be more common or severe than expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DULOXETINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Tiantan Hospital, Beijing, Beijing 100070

    RECRUITING

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.